Journal of Clinical Pediatrics >
Analysis of autoantibody expression and prognostic factors of immune thrombocytopenia in 299 children
Received date: 2022-05-18
Online published: 2024-04-09
Objective To analyze the characteristics of autoantibody expression and prognosis influencing factors in children with immune thrombocytopenia (ITP). Methods The clinical data of 299 children with newly diagnosed ITP hospitalized from September 2020 to September 2021 were retrospectively analyzed. Results A total of 299 children (171 boys and 128 girls) with ITP were included, and the median age was 2.7 (1.0-4.6) years. Among the 296 ITP children who completed autoantibody spectrum detection, 114 (38.5%) showed positive autoantibody spectrum expression. One hundred and fourteen patients (38.5%) of the 296 ITP children who finished autoantibody spectrum detection had positive autoantibody spectrum expression. Among them, 101 patients (88.6%) were positive for anti-nuclear antibody, 59 (51.8%) were positive for anti-SSA /RO52KD antibody, and 52 (45.6%) were positive for anti-SSA /RO60KD antibody. Of 299 children with ITP, 205 were cured. Compared with the cured group, the uncured group had a higher proportion of age ≥ 1 year old, positive antinuclear antibody, anti-SSA/RO52KD antibody, anti-SSA/RO60KD antibody and bleeding score≥3, and a lower proportion of preceding infection and gammaglobulin alone, with statistically significant differences (P<0.05). The binary logistics regression analysis showed that age ≥ 1 year old, positive antinuclear antibody, and bleeding score ≥ 3 were independent risk factors for ITP prognosis (P<0.05), and a history of preceding infection was an independent protective factor for ITP prognosis (P<0.05). Conclusions Autoantibody spectrum antibody expression is common in children with ITP. Age, history of preceding infection, antinuclear antibody and bleeding score are associated with ITP prognosis.
Key words: immune thrombocytopenia; child; autoantibody; prognostic factor
Longwei XU , Feng CAO , Yaodong ZHANG , Yinghui ZHANG . Analysis of autoantibody expression and prognostic factors of immune thrombocytopenia in 299 children[J]. Journal of Clinical Pediatrics, 2024 , 42(4) : 318 -322 . DOI: 10.12372/jcp.2024.22e0717
[1] | 国家卫生健康委. 儿童原发性免疫性血小板减少症诊疗规范(2019年版)[J]. 全科医学临床与教育, 2019, 17(12): 1059-1062. |
[2] | Kühne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group[J]. Haematologica, 2011, 96(12): 1831-1837. |
[3] | Heitink-Pollé KM, Nijsten J, Boonacker CW, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis[J]. Blood, 2014, 124(22): 3295-3307. |
[4] | Güng?r T, Arman Bilir ?, Ko?an ?ulha V, et al. Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity[J]. Pediatr Neonatol, 2019, 60(4): 411-416. |
[5] | 方拥军, 黄婕. 儿童原发性免疫性血小板减少症的发病机制[J]. 中华实用儿科临床杂志, 2017, 32(15): 1121-1124. |
[6] | 倪蔚文, 储金华, 杨林海, 等. 儿童初诊原发免疫性血小板减少症患者细胞及体液免疫功能分析[J]. 安徽医科大学学报, 2019, 54(10): 1628-1631. |
[7] | Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes[J]. Pediatr Blood Cancer, 2017, 64(7). doi: 10.1002/pbc.26389. |
[8] | Altintas A, Ozel A, Okur N, et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura[J]. J Thromb Thrombolysis, 2007, 24(2): 163-168. |
[9] | 谭春莲, 左休琴, 李晓明. 163例成人原发免疫性血小板减少症自身抗体表达特点及预后影响因素分析[J]. 解放军医学院学报, 2019, 40(12): 1133-1137. |
[10] | Kim CY, Lee EH, Yoon HS. High remission rate of chronic immune thrombocytopenia in children: result of 20-year follow-up[J]. Yonsei Med J, 2016, 57(1): 127-131. |
[11] | 郑静娴, 李晓辉, 孙洪强. 儿童免疫性血小板减少症的临床观察及抗核抗体在其中作用的研究[J]. 临床输血与检验, 2021, 23(2): 231-235. |
[12] | 刘正红, 徐之良. 抗核抗体与抗可提取性核抗原抗体在初诊免疫性血小板减少症患儿中的临床意义[J]. 中国医学前沿杂志(电子版), 2021, 13(9): 94-98. |
[13] | Keech CL, Gordon TP, McCluskey J. The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity[J]. J Immunol, 1996, 157(8): 3694-3699. |
[14] | Liu Q, Xu H, Guan X, et al. Clinical significance of antinuclear and antiextractable nuclear antigen antibody in childhood immune thrombocytopenia[J]. Semin Thromb Hemost, 2017, 43(6): 629-634. |
[15] | Zhu FX, Huang JY, Ye Z, et al. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study[J]. Ann Rheum Dis, 2020, 79(6): 793-799. |
[16] | Donato H, Picón A, Martinez M, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina[J]. Pediatr Blood Cancer, 2009, 52(4): 491-496. |
[17] | KuhneT, BuchananGR, ZimmermanS, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group[J]. J Pediatr, 2003, 143(5): 605-608. |
[18] | 崔清彦, 颉迎新, 王文欣, 等. 免疫性血小板减少症发病机制的研究进展[J]. 山东医药, 2020, 60(4): 102-105. |
[19] | 中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J]. 中华儿科杂志, 2021, 59(10): 810-819. |
/
〈 |
|
〉 |